These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 26775891)
1. Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer. Seishima R; Okabayashi K; Nagano O; Hasegawa H; Tsuruta M; Shimoda M; Kameyama K; Saya H; Kitagawa Y Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):487-93. PubMed ID: 26775891 [TBL] [Abstract][Full Text] [Related]
2. Cancer stem cell markers CD44v9+/CD133- are associated with low apoptosis in both sporadic and ulcerative colitis-associated colorectal cancers. Nakagomi E; Mikami T; Funahashi K; Okazumi S; Shibuya K; Hiruta N; Igarashi Y Histol Histopathol; 2022 Jun; 37(6):587-595. PubMed ID: 35224715 [TBL] [Abstract][Full Text] [Related]
3. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. Ogihara K; Kikuchi E; Okazaki S; Hagiwara M; Takeda T; Matsumoto K; Kosaka T; Mikami S; Saya H; Oya M Cancer Sci; 2019 Apr; 110(4):1431-1441. PubMed ID: 30719824 [TBL] [Abstract][Full Text] [Related]
4. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression. Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933 [TBL] [Abstract][Full Text] [Related]
5. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine. Wada F; Koga H; Akiba J; Niizeki T; Iwamoto H; Ikezono Y; Nakamura T; Abe M; Masuda A; Sakaue T; Tanaka T; Kakuma T; Yano H; Torimura T Cancer Sci; 2018 Sep; 109(9):2801-2810. PubMed ID: 29981246 [TBL] [Abstract][Full Text] [Related]
6. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517 [TBL] [Abstract][Full Text] [Related]
7. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression. Yasui W; Kudo Y; Naka K; Fujimoto J; Ue T; Yokozaki H; Tahara E Int J Oncol; 1998 Jun; 12(6):1253-8. PubMed ID: 9592182 [TBL] [Abstract][Full Text] [Related]
8. CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma. Kakehashi A; Ishii N; Sugihara E; Gi M; Saya H; Wanibuchi H Cancer Sci; 2016 May; 107(5):609-18. PubMed ID: 26882440 [TBL] [Abstract][Full Text] [Related]
9. Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. van Schaik FD; Oldenburg B; Offerhaus GJ; Schipper ME; Vleggaar FP; Siersema PD; van Oijen MG; Ten Kate FJ Inflamm Bowel Dis; 2012 Mar; 18(3):480-8. PubMed ID: 21509910 [TBL] [Abstract][Full Text] [Related]
10. The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation. Akamine T; Tagawa T; Ijichi K; Toyokawa G; Takamori S; Hirai F; Okamoto T; Oda Y; Maehara Y Ann Surg Oncol; 2019 May; 26(5):1544-1551. PubMed ID: 30798450 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of CD44 Variant 9: A Novel Cancer Stem Cell Marker in Human Cholangiocarcinoma in Relation to Inflammation. Suwannakul N; Ma N; Thanan R; Pinlaor S; Ungarreevittaya P; Midorikawa K; Hiraku Y; Oikawa S; Kawanishi S; Murata M Mediators Inflamm; 2018; 2018():4867234. PubMed ID: 30402042 [TBL] [Abstract][Full Text] [Related]
12. Sulfasalazine inhibits activation of nuclear factor-kappaB in patients with ulcerative colitis. Gan HT; Chen YQ; Ouyang Q J Gastroenterol Hepatol; 2005 Jul; 20(7):1016-24. PubMed ID: 15955209 [TBL] [Abstract][Full Text] [Related]
13. CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma. Taniguchi D; Saeki H; Nakashima Y; Kudou K; Nakanishi R; Kubo N; Ando K; Oki E; Oda Y; Maehara Y Cancer Med; 2018 Dec; 7(12):6258-6268. PubMed ID: 30474922 [TBL] [Abstract][Full Text] [Related]
14. The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer. Go SI; Ko GH; Lee WS; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS Cancer Res Treat; 2019 Oct; 51(4):1411-1419. PubMed ID: 30913874 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characterisation of duodenal adenocarcinoma with high CD44 variant 9 expression. Maruyama Y; Uehara T; Daikuhara S; Kobayashi Y; Nakajima T; Matsumoto A; Tanaka E; Ota H Pathology; 2015 Dec; 47(7):647-52. PubMed ID: 26517627 [TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell marker in circulating tumor cells: expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer. Katoh S; Goi T; Naruse T; Ueda Y; Kurebayashi H; Nakazawa T; Kimura Y; Hirono Y; Yamaguchi A Anticancer Res; 2015 Jan; 35(1):239-44. PubMed ID: 25550556 [TBL] [Abstract][Full Text] [Related]
17. Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment. Lee HJ; Choi SC; Lee MH; Oh HM; Choi EY; Choi EJ; Yun KJ; Seo GS; Kim SW; Lee JG; Han WC; Park KI; Jun CD Inflamm Bowel Dis; 2005 Dec; 11(12):1070-9. PubMed ID: 16306769 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer. Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396 [TBL] [Abstract][Full Text] [Related]
19. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Walker AM; Szneke P; Bianchi LA; Field LG; Sutherland LR; Dreyer NA Am J Gastroenterol; 1997 May; 92(5):816-20. PubMed ID: 9149192 [TBL] [Abstract][Full Text] [Related]
20. The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells. Aguilar-Chaparro MA; Rivera-Pineda SA; Hernández-Galdámez HV; Piña-Vázquez C; Villa-Treviño S Stem Cell Res; 2023 Oct; 72():103222. PubMed ID: 37844417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]